Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Clinical Pharmacokinetics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 8384945
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The kinetics of citalopram: single and multiple dose studies in man.

  2009cited by this paper
• Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients

  2005cited by this paper
• Kinetics of citalopram in elderly patients

  2004cited by this paper
• Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor

  2004cited by this paper
• Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology

  2004cited by this paper
• Fluvoxamine-tricyclic antidepressant interaction

  2004cited by this paper
• High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients.

  1998cited by this paper
• Single and Multiple Oral Dose Fluvoxamine Kinetics in Young and Elderly Subjects

  1992cited by this paper
• Sertraline Does Not Alter Steady‐State Concentrations or Renal Clearance of Lithium in Healthy Volunteers

  1992cited by this paper
• Inhibitors of imipramine metabolism by human liver microsomes.

  1992cited by this paper
• Interaction Between Fluvoxamine and Imipramine/Desipramine in Four Patients

  1992cited by this paper
• The relationship between paroxetine and the sparteine oxidation polymorphism

  1992cited by this paper
• The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes.

  1992cited by this paper
• Fluvoxamine does not interact with alcohol or potentiate alcohol‐related impairment of cognitive function

  1992cited by this paper
• Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

  1992cited by this paper
• Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.

  1991cited by this paper
• Interaction between carbamazepine and fluvoxamine

  1991cited by this paper
• Increased carbamazepine plasma concentrations after fluoxetine coadministration

  1991cited by this paper
• Fluoxetine and norfluoxetine are potent inhibitors of P450IID6--the source of the sparteine/debrisoquine oxidation polymorphism.

  1991cited by this paper
• Excretion of fluvoxamine in breast milk.

  1991cited by this paper
• Fluoxetine‐Induced Tricyclic Toxicity: Extent and Duration

  1991cited by this paper
• Clinical Implications of the Pharmacology of Sertraline

  1991cited by this paper
• Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

  1991cited by this paper
• Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

  1991cited by this paper
• Bioavailability of fluvoxamine given with and without food

  1991cited by this paper
• [Possible interaction between theophylline and fluvoxamine].

  1991cited by this paper
• Interaction of fluoxetine with carbamazepine.

  1990cited by this paper
• Antidepressants, Metabolites, and Apparent Drug Resistance

  1990cited by this paper
• Plasma‐Level Response Relationships with Fluoxetine and Zimelidine

  1990cited by this paper
• Excretion of fluoxetine in human breast milk.

  1990cited by this paper
• Fluoxetine drug-drug interactions. II.

  1990cited by this paper
• Recent Developments in Hepatic Drug Oxidation Implications for Clinical Pharmacokinetics

  1990cited by this paper
• Possible adverse drug interactions between fluoxetine and other psychotropics.

  1990cited by this paper
• Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics.

  1990cited by this paper
• A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate.

  1989cited by this paper
• Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites

  1989cited by this paper
• Ability of charcoal to prevent absorption of paroxetine

  1989cited by this paper
• Serum Fluoxetine and Norfluoxetine Concentrations and Antidepressant Response

  1989cited by this paper
• The psychomotor effects of paroxetine alone and in combination with haloperidol, amylobarbitone, oxazepam, or alcohol

  1989cited by this paper
• The effect of liver enzyme inhibition by cimetidine and enzyme induction by phenobarbitone on the pharmacokinetics of paroxetine

  1989cited by this paper
• Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine.

  1989cited by this paper
• The pharmacokinetics of paroxetine in patients with liver cirrhosis

  1989cited by this paper
• A pharmacokinetic dose titration study in adult and elderly depressed patients

  1989cited by this paper
• Paroxetine: pharmacokinetic and antidepressant effect in the elderly

  1989cited by this paper
• Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin

  1989cited by this paper
• The effects of paroxetine and other antidepressants in combination with alcohol on psychomotor activity related to car driving

  1989cited by this paper
• Chronic Treatment with Fluvoxamine, Clovoxamine, and Placebo: Interaction with Digoxin and Effects on Sleep and Alertness

  1989cited by this paper
• Paroxetine plasma levels: lack of correlation with efficacy or adverse events

  1989cited by this paper
• Absorption of paroxetine under various dietary conditions and following antacid intake

  1989cited by this paper
• The pharmacokinetics of paroxetine in renal impairment

  1989cited by this paper
• A review of the metabolism and pharmacokinetics of paroxetine in man

  1989cited by this paper
• The pharmacokinetics of paroxetine in the elderly

  1989cited by this paper
• Paroxetine: lack of effect on hepatic drug metabolizing enzymes

  1989cited by this paper
• Drug binding to human alpha-1-acid glycoprotein in health and disease.

  1988cited by this paper
• Fluoxetine disposition and elimination in cirrhosis

  1988cited by this paper
• The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam

  1988cited by this paper
• Clinical Pharmacology and Pharmacokinetics of Fluoxetine: A Review

  1988cited by this paper
• Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

  1988cited by this paper
• Citalopram--a highly selective 5-HT uptake inhibitor--in the treatment of depressed patients.

  1987cited by this paper
• Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

  1986cited by this paper
• Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

  1986cited by this paper
• Effect of fluoxetine on psychomotor performance, physiologic response, and kinetics of ethanol

  1985cited by this paper
• Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram

  1985cited by this paper
• Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake.

  1984cited by this paper
• Fluoxetine kinetics and protein binding in normal and impaired renal function

  1984cited by this paper
• Fluvoxamine and chlorimipramine in endogenous depression.

  1982cited by this paper
• The effect of fluoxetine on warfarin metabolism in the rat and man.

  1978cited by this paper

• High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID‐19 Treatment

  2025cites this paper
• Sex-specific effect of long-term fluoxetine exposure on inhibitory control in guppies (Poecilia reticulata)

  2025cites this paper
• Quantification of 5-HT1a receptors in temporal lobe epilepsy with PET and [18F]FCWAY: Effect of modeling methods on group discrimination.

  2025cites this paper
• Effects of sodium fluoride on serum concentrations of selected psychotropic drugs

  2025cites this paper
• Safety in treatment: Classical pharmacotherapeutics and new avenues for addressing maternal depression and anxiety during pregnancy.

  2025cites this paper
• Tracing Pharmaceuticals in Water Systems: Focus on Neurodegenerative and Psychiatric Treatments

  2024cites this paper
• Fluoxetine alters rat's milk properties causing impact on offspring's development.

  2024cites this paper
• Attenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use

  2023cites this paper
• Selective Serotonin Reuptake Inhibitors and 5-HT2 Receptor Agonists Have Distinct, Sleep-state Dependent Effects on Postictal Breathing in Amygdala Kindled Mice

  2023cites this paper
• Sertraline-Induced Optic Nerve Dysfunction

  2023cites this paper
• Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection

  2022cites this paper
• Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19

  2022cites this paper
• Virtual screening and molecular docking of structures with potential inhibitor of the ebolavirus glycoprotein

  2022cites this paper
• The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds

  2022cites this paper
• Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine

  2022cites this paper
• Simultaneous determination of four serotonin selective reuptake inhibitors by an UPLC MS-MS method with clinical application in therapeutic drug monitoring.

  2022cites this paper
• Untargeted Metabolomics Reveals Antidepressant Effects in a Marine Photosynthetic Organism: The Diatom Phaeodactylum tricornutum as a Case Study

  2022cites this paper
• Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review.

  2022cites this paper
• Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm

  2021cites this paper
• Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations

  2021cites this paper
• Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

  2021cites this paper
• Presumed Sertraline-Associated Maculopathy: A Case Series

  2021cites this paper
• Antidepressants and Circadian Rhythm: Exploring Their Bidirectional Interaction for the Treatment of Depression

  2021cites this paper
• Evaluation of Switch‐to‐Brand Rates as a Potential Signal for Therapeutic Equivalency of Generic Antidepressants: A Real‐World Retrospective Cohort Study

  2021cites this paper
• An update on the treatment of premature ejaculation: A systematic review

  2021cites this paper
• Differences in P-glycoprotein activity in human and rodent blood–brain barrier assessed by mechanistic modelling

  2021cites this paper
• Respiratory depression in a neonate born to mother on maximum dose sertraline: a case report

  2021cites this paper
• High risk of drug toxicity in social isolation stress due to liver dysfunction: Role of oxidative stress and inflammation

  2021cites this paper
• Considerations and Current Trends in the Management of the Geriatric Patient on a Consultation–Liaison Service

  2020cites this paper
• Estimation of community-wide multi-chemical exposure via water-based chemical mining: Key research gaps drawn from a comprehensive multi-biomarker multi-city dataset.

  2020cites this paper
• Revisited: Therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics

  2020cites this paper
• In Silico Drug Repositioning for Chagas Disease.

  2020cites this paper
• Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy

  2020cites this paper
• Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

  2020cites this paper
• Impact of the widespread pharmaceutical pollutant fluoxetine on behaviour and sperm traits in a freshwater fish.

  2019cites this paper
• Effects of Treatment Discontinuation in Clinical Psychopharmacology

  2019cites this paper
• Major Depressive Disorder and Oxidative Stress: In Silico Investigation of Fluoxetine Activity against ROS

  2019cites this paper
• Sertraline-Cyclodextrin Complex Orodispersible Sublingual Tablet: Optimization, Stability, and Pharmacokinetics

  2019cites this paper
• Potential Adverse Cardiovascular Effects of Treatment With Fluoxetine and Other Selective Serotonin Reuptake Inhibitors (SSRIs) in Patients With Geriatric Depression: Implications for Atherogenesis and Cerebromicrovascular Dysregulation

  2019influential citation
• Pharmacokinetic considerations for current state-of-the-art antidepressants

  2019cites this paper
• Serotonin and serotonin reuptake inhibitors alter placental aromatase.

  2019cites this paper
• UvA-DARE ( Digital Academic Repository ) Central regulation of glucose metabolism

  2018cites this paper
• Intrauterine and lactational exposure to fluoxetine enhances endothelial modulation of aortic contractile response in adult female rats.

  2018cites this paper
• Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients

  2018cites this paper
• The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing strategies.

  2018cites this paper
• Behaviour of freshwater snails (Radix balthica) exposed to the pharmaceutical sertraline under simulated predation risk

  2018cites this paper
• The effects of a single dose of fluoxetine on practice-dependent plasticity.

  2018cites this paper
• Bilateral cystoid macular edema misdiagnosed as pars planitis in a patient on sertraline therapy

  2018cites this paper
• Bioaccumulation and trophodynamics of the antidepressants sertraline and fluoxetine in laboratory‐constructed, 3‐level aquatic food chains

  2017cites this paper
• Phosphodiesterase-5 inhibitors for premature ejaculation: a systematic review and meta-analysis

  2017cites this paper
• Infusion of fluoxetine, a serotonin reuptake inhibitor, in the shell region of the nucleus accumbens increases blood glucose concentrations in rats.

  2017cites this paper
• Application of Mice Humanized for CYP2D6 to the Study of Tamoxifen Metabolism and Drug–Drug Interaction with Antidepressants

  2017cites this paper
• Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

  2016influential citation
• Serum fluoxetine and norfluoxetine levels support the safety of fluoxetine in overdose

  2016cites this paper
• In vitro and in vivo measurements of serotonin for ecological and mental health via fast scan cyclic voltammetry

  2016cites this paper
• Assessing Potential Vulnerability and Response of Fish to Simulated Avian Predation after Exposure to Psychotropic Pharmaceuticals

  2016cites this paper
• Psychogenic Itch Management.

  2016cites this paper
• A study of sertraline in dialysis (ASSertID): a protocol for a pilot randomised controlled trial of drug treatment for depression in patients undergoing haemodialysis

  2015cites this paper
• Hormonal and Histopathological Study of Adult Albino Rats ' Thyroids and Testes After Long-Term Fluoxetine Hydrochloride Administration

  2015cites this paper
• Therapeutic Reference Range for Plasma Concentrations of Paroxetine in Patients With Major Depressive Disorders

  2014cites this paper
• Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment

  2014cites this paper
• The Influence of 5-HTTLPR Genotype on the Association between the Plasma Concentration and Therapeutic Effect of Paroxetine in Patients with Major Depressive Disorder

  2014cites this paper
• Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram

  2014cites this paper
• Pharmacotherapy for Mood Disorders in Pregnancy: A Review of Pharmacokinetic Changes and Clinical Recommendations for Therapeutic Drug Monitoring

  2014influential citation
• Melatonin synergizes with citalopram to induce antidepressant‐like behavior and to promote hippocampal neurogenesis in adult mice

  2014cites this paper
• Fluoxetine: a case history of its discovery and preclinical development

  2014cites this paper
• Paroxetine hydrochloride.

  2013cites this paper
• Enantioselective extraction of (+)-(S)-citalopram and its main metabolites using a tailor-made stir bar chiral imprinted polymer for their LC-ESI-MS/MS quantitation in urine samples.

  2013cites this paper
• Current Advances in the Treatment of Major Depression: Shift Towards Receptor Specific Drugs

  2013cites this paper
• Rapid determination of letrozole, citalopram and their metabolites by high performance liquid chromatography-fluorescence detection in urine: Method validation and application to real samples.

  2013cites this paper
• Neonatal tryptophan depletion and corticosterone supplementation modify emotional responses in adult male mice.

  2013cites this paper
• Genetics of serotonin receptors and depression: state of the art.

  2013cites this paper
• The role of platelet/lymphocyte serotonin transporter in depression and beyond.

  2013cites this paper
• Gender-dependent effects of fluoxetine on selected biochemical parameters in guinea pigs

  2012cites this paper
• Genotoxic evaluation of selective serotonin-reuptake inhibitors by use of the somatic mutation and recombination test in Drosophila melanogaster.

  2012cites this paper
• Long term impact of prenatal exposure to SSRIs on growth and body weight in childhood: evidence from animal and human studies.

  2012cites this paper
• Selective serotonin reuptake inhibitors (SSRIs): therapeutic drug monitoring and pharmacological interactions.

  2012cites this paper
• [Treatment of inter-specific aggression in cats with the selective serotonin reuptake inhibitor fluvoxamine. A case report].

  2012cites this paper
• Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: what needs to be known for practice

  2012cites this paper
• Prenatal exposure to selective serotonin reuptake inhibitors and risk of childhood overweight.

  2012cites this paper
• Determination of sertraline in rat plasma by HPLC and fluorescence detection and its application to in vivo pharmacokinetic studies.

  2012cites this paper
• Analytical procedures for the determination of the selective serotonin reuptake inhibitor antidepressant citalopram and its metabolites.

  2011cites this paper
• AMPA RECEPTOR TRAFFICKING : A MECHANISM OF EXCITATORY SYNAPTIC PLASTICITY

  2011cites this paper
• Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders

  2011cites this paper
• Investigating Outcomes Following the Use of Selective Serotonin Reuptake Inhibitors for Treating Depression in Pregnancy

  2011cites this paper
• Serotonin triggers a transient epigenetic mechanism that reinstates adult visual cortex plasticity in rats

  2011cites this paper
• Fluoxetine and citalopram exhibit potent antiinflammatory activity in human and murine models of rheumatoid arthritis and inhibit toll-like receptors.

  2010cites this paper
• Waterborne fluoxetine disrupts the reproductive axis in sexually mature male goldfish, Carassius auratus.

  2010cites this paper
• 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.

  2010cites this paper
• A review of SSRIs and SNRIs in neuropathic pain

  2010cites this paper
• Latest advancements on serotonin and dopamine transporters in lymphocytes.

  2010cites this paper
• Astrocytic transactivation by alpha2A-adrenergic and 5-HT2B serotonergic signaling.

  2010cites this paper
• Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure.

  2010cites this paper
• Chronic fluoxetine treatment has a larger effect on the density of a serotonin transporter in the Flinders Sensitive Line (FSL) rat model of depression than in normal rats

  2010cites this paper
• In vitro screening of 50 highly prescribed drugs for thiol adduct formation--comparison of potential for drug-induced toxicity and extent of adduct formation.

  2009cites this paper
• NMDA receptor/nitrergic system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test

  2009cites this paper
• The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies

  2009cites this paper
• Relevant issues in the monitoring and the toxicology of antidepressants.

  2008cites this paper
• Effects of fluoxetine on the reproductive axis of female goldfish (Carassius auratus).

  2008cites this paper
• Effect of selected antidepressant drugs on cytochrome P450 2B (CYP2B) in rat liver. An in vitro and in vivo study.

  2008cites this paper